Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Keyphrases

• Rheumatology 100%
• Hospitalization 100%
• COVID-19 100%
• Severe COVID-19 100%
• Idiopathic Inflammatory Myopathies 100%
• Old Age 40%
• Rituximab 40%
• High Disease Activity 40%
• Sensitivity Analysis 40%
• Prednisolone 40%
• Male Sex 40%
• Severe Outcomes 40%
• Equivalent Dose 40%
• Clinical Characteristics 20%
• Multivariable 20%
• Comorbidity 20%
• Remission 20%
• COVID-19 Diagnosis 20%
• Ordinal Logistic Regression 20%
• COVID-19 Severity 20%
• Ventilation 20%
• COVID-19 Outcomes 20%
• 4-point 20%
• Outcome Severity 20%
• 3-point 20%
• Management Decisions 20%
• Severity Scale 20%
• Demographic Data 20%
• Risk Stratification 20%
• Ordinal Scale 20%
• Conventional Synthetic Disease-modifying Antirheumatic Drugs 20%
• Comorbidity Burden 20%
• Registry Data 20%

Medicine and Dentistry

• Rheumatology 100%
• COVID-19 100%
• Myositis 100%
• Disease Activity 20%
• Rituximab 20%
• Prednisolone 20%
• Equivalent Dose 20%
• Comorbidity 20%
• Logistic Regression Analysis 10%
• Disease Modifying Antirheumatic Drug 10%
• Risk Stratification 10%

Nursing and Health Professions

• Myositis 100%
• Rituximab 40%
• Disease Activity 40%
• Prednisolone 40%
• Equivalent Dose 40%
• Comorbidity 40%
• Logistic Regression Analysis 20%
• Remission 20%
• Disease Modifying Antirheumatic Drug 20%